Coherus Oncology (CHRS) EBT Margin Growth (3y) (2016 - 2026)
Coherus Oncology (CHRS) EBT Margin Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9,237.00 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 441.00 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -408.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -120.00 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn | -6,657.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,657.00 |
| Dec 31, 2025 | -23,376.00 |
| Sep 30, 2025 | -19,397.00 |
| Jun 30, 2025 | -35,413.00 |
| Mar 31, 2025 | -46,391.00 |
| Dec 31, 2024 | -53,378.00 |
| Sep 30, 2024 | -73,980.00 |
| Jun 30, 2024 | -49,863.00 |
| Mar 31, 2024 | -273,955.00 |
| Dec 31, 2023 | -9,677.00 |
| Sep 30, 2023 | -7,843.00 |
| Jun 30, 2023 | -11,747.00 |
| Mar 31, 2023 | -26,489.00 |
| Dec 31, 2022 | -16,312.00 |
| Sep 30, 2022 | -23,364.00 |
| Jun 30, 2022 | -11,168.00 |
| Mar 31, 2022 | -10,591.00 |
| Jun 30, 2020 | 486,146.00 |
| Mar 31, 2020 | 5.17 Mn |
| Dec 31, 2019 | 901,780.00 |